{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:02:19Z","timestamp":1794279739505,"version":"4.9.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Proteolysis-targeting chimeras (PROTACs) are being developed for therapeutic use. However, they have poor pharmacokinetic profiles and their tissue distribution kinetics are not known.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A typical von Hippel-Lindau tumor suppressor (VHL)\u2014PROTAC <jats:sup>14<\/jats:sup>C-A947 (BRM degrader)\u2014was synthesized and its tissue distribution kinetics was studied by quantitative whole-body autoradiography (QWBA) and tissue excision in rats following IV dosing. Bile duct-cannulated (BDC) rats allowed the elucidation of in vivo clearance pathways. Distribution kinetics was evaluated in the tissues and tumors of mice to support PK-PD correlation. In vitro studies enabled the evaluation of cell uptake mechanisms and cell retention properties.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Here, we show that A947 quickly distributes into rat tissues after IV dosing, where it accumulates and is retained in tissues such as the lung and liver although it undergoes fast clearance from circulation. Similar uptake\/retention kinetics enable tumor growth inhibition over 2\u20133 weeks in a lung cancer model. A947 quickly excretes in the bile of rats. Solute carrier (SLC) transporters are involved in hepatocyte uptake of PROTACs. Sustained BRM protein degradation is seen after extensive washout that supports prolonged cell retention of A947 in NCI-H1944 cells. A947 tissue exposure and pharmacodynamics are inversely correlated in tumors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Plasma sampling for VHL-PROTAC does not represent the tissue concentrations necessary for efficacy. Understanding of tissue uptake and retention could enable less frequent IV administration to be used for therapeutic dosing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s43856-024-00505-y","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T10:01:44Z","timestamp":1715853704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8677-9737","authenticated-orcid":false,"given":"Donglu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7549-2658","authenticated-orcid":false,"given":"Bin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Dragovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Pizzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Bortolon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-6283","authenticated-orcid":false,"given":"Robert L.","family":"Yauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Cyrus","family":"Khojasteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8287-6878","authenticated-orcid":false,"given":"Cornelis E. C. A.","family":"Hop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"505_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41587-021-01173-2","volume":"40","author":"K Garber","year":"2022","unstructured":"Garber, K. The PROTAC gold rush. Nat. Biotechnol. 40, 12\u201316 (2022).","journal-title":"Nat. Biotechnol."},{"key":"505_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"505_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","volume":"24","author":"PM Cromm","year":"2017","unstructured":"Cromm, P. M. & Crews, C. M. Targeted protein degradation: from chemical biology to drug discovery. Cell Chem. Biol. 24, 1181\u20131190 (2017).","journal-title":"Cell Chem. Biol."},{"key":"505_CR4","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/D2CS00193D","volume":"51","author":"K Li","year":"2022","unstructured":"Li, K. & Crews, C. M. PROTACs: past, present and future. Chem. Soc. Rev. 51, 5214\u20135236 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"505_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","volume":"61","author":"I Churcher","year":"2018","unstructured":"Churcher, I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones? J. Med. Chem. 61, 444\u2013452 (2018).","journal-title":"J. Med. Chem."},{"key":"505_CR6","doi-asserted-by":"publisher","first-page":"103366","DOI":"10.1016\/j.drudis.2022.103366","volume":"27","author":"P Agarwal","year":"2022","unstructured":"Agarwal, P., Huckle, J., Newman, J. & Reid, D. L. Trends in small molecule drug properties: a developability molecule assessment perspective. Drug Discov. Today 27, 103366 (2022).","journal-title":"Drug Discov. Today"},{"key":"505_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1208\/s12248-019-0402-2","volume":"22","author":"WZ Yang","year":"2020","unstructured":"Yang, W. Z. et al. The evolving druggability and developability space: chemically modified new modalities and emerging small molecules. Aaps J. 22, 21 (2020).","journal-title":"Aaps J."},{"key":"505_CR8","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","volume":"29","author":"SD Edmondson","year":"2019","unstructured":"Edmondson, S. D., Yang, B. & Fallan, C. Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019 chemical space: Recent progress and future challenges. Bioorg. Med. Chem. Lett. 29, 1555\u20131564 (2019).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"505_CR9","first-page":"243","volume":"9","author":"DG Jimenez","year":"2021","unstructured":"Jimenez, D. G., Sebastiano, M. R., Caron, G. & Ermondi, G. Are we ready to design oral PROTACs(R)? ADMET DMPK 9, 243\u2013254 (2021).","journal-title":"ADMET DMPK"},{"key":"505_CR10","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","volume":"25","author":"A Pike","year":"2020","unstructured":"Pike, A., Williamson, B., Harlfinger, S., Martin, S. & McGinnity, D. F. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug Discov. Today. 25, 1793\u20131800 (2020).","journal-title":"Drug Discov. Today."},{"key":"505_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4155\/fmc-2021-0208","volume":"14","author":"V Poongavanam","year":"2022","unstructured":"Poongavanam, V. & Kihlberg, J. PROTAC cell permeability and oral bioavailability: a journey into uncharted territory. Future Med. Chem. 14, 123\u2013126 (2022).","journal-title":"Future Med. Chem."},{"key":"505_CR12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.drudis.2020.03.012","volume":"25","author":"C Cantrill","year":"2020","unstructured":"Cantrill, C. et al. Fundamental aspects of DMPK optimization of targeted protein degraders. Drug Discov. Today 25, 969\u2013982 (2020).","journal-title":"Drug Discov. Today"},{"key":"505_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/pharmaceutics15010156","volume":"15","author":"F Postges","year":"2023","unstructured":"Postges, F. et al. Solubility enhanced formulation approaches to overcome oral delivery obstacles of PROTACs. Pharmaceutics 15, 156 (2023).","journal-title":"Pharmaceutics"},{"key":"505_CR14","doi-asserted-by":"publisher","first-page":"12831","DOI":"10.1021\/acs.jmedchem.1c00882","volume":"64","author":"X Han","year":"2021","unstructured":"Han, X. et al. Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer. J. Med. Chem. 64, 12831\u201312854 (2021).","journal-title":"J. Med. Chem."},{"key":"505_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1021\/acsmedchemlett.0c00556","volume":"12","author":"Y Atilaw","year":"2021","unstructured":"Atilaw, Y. et al. Solution conformations shed light on PROTAC cell permeability. ACS Med. Chem. Lett. 12, 107\u2013114 (2021).","journal-title":"ACS Med. Chem. Lett."},{"key":"505_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/cmdc.201900497","volume":"15","author":"TH Pillow","year":"2020","unstructured":"Pillow, T. H. et al. Antibody conjugation of a chimeric BET degrader enables in vivo activity. ChemMedChem 15, 17\u201325 (2020).","journal-title":"ChemMedChem"},{"key":"505_CR17","doi-asserted-by":"publisher","first-page":"16930","DOI":"10.1021\/jacs.2c05499","volume":"144","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Discovery of XL01126: a potent, fast, cooperative, selective, orally bioavailable, and blood-brain barrier penetrant PROTAC degrader of leucine-rich repeat kinase 2. J. Am. Chem. Soc. 144, 16930\u201316952 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"505_CR18","first-page":"895","volume":"18","author":"A Mullard","year":"2019","unstructured":"Mullard, A. Arvinas\u2019s PROTACs pass first safety and PK analysis. Nat. Rev. Drug Discov. 18, 895\u2013895 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"505_CR19","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1124\/dmd.122.001154","volume":"51","author":"LP Volak","year":"2023","unstructured":"Volak, L. P. et al. Industry perspective on the pharmacokinetic and absorption, distribution, metabolism, and excretion characterization of heterobifunctional protein degradersS. Drug Metab. Dispos. 51, 792\u2013803 (2023).","journal-title":"Drug Metab. Dispos."},{"key":"505_CR20","doi-asserted-by":"publisher","first-page":"e1500447","DOI":"10.1126\/sciadv.1500447","volume":"1","author":"C Kadoch","year":"2015","unstructured":"Kadoch, C. & Crabtree, G. R. Mammalian SWI\/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci. Adv. 1, e1500447 (2015).","journal-title":"Sci. Adv."},{"key":"505_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41556-018-0258-1","volume":"21","author":"AM Valencia","year":"2019","unstructured":"Valencia, A. M. & Kadoch, C. Chromatin regulatory mechanisms and therapeutic opportunities in cancer. Nat. Cell Biol. 21, 152\u2013161 (2019).","journal-title":"Nat. Cell Biol."},{"key":"505_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19402-8","volume":"11","author":"TM Fernando","year":"2020","unstructured":"Fernando, T. M. et al. Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients. Nat. Commun. 11, 5551 (2020).","journal-title":"Nat. Commun."},{"key":"505_CR23","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","volume":"26","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. et al. The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer. Clin. Cancer Res. 26, 5701\u20135708 (2020).","journal-title":"Clin. Cancer Res."},{"key":"505_CR24","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1128\/MCB.01372-13","volume":"34","author":"BG Wilson","year":"2014","unstructured":"Wilson, B. G. et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol. Cell Biol. 34, 1136\u20131144 (2014).","journal-title":"Mol. Cell Biol."},{"key":"505_CR25","doi-asserted-by":"publisher","first-page":"116627","DOI":"10.1016\/j.taap.2023.116627","volume":"475","author":"J Maher","year":"2023","unstructured":"Maher, J. et al. Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout rats. Toxicol .Appl. Pharmacol. 475, 116627 (2023).","journal-title":"Toxicol .Appl. Pharmacol."},{"key":"505_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34562-5","volume":"13","author":"J Cantley","year":"2022","unstructured":"Cantley, J. et al. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers. Nat. Commun. 13, 6814 (2022).","journal-title":"Nat. Commun."},{"key":"505_CR27","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1124\/dmd.120.000163","volume":"48","author":"X Liang","year":"2020","unstructured":"Liang, X. et al. In vitro hepatic uptake in human and monkey hepatocytes in the presence and absence of serum protein and its in vitro to in vivo extrapolation. Drug Metab. Dispos. 48, 1283\u20131292 (2020).","journal-title":"Drug Metab. Dispos."},{"key":"505_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1124\/dmd.120.090878","volume":"48","author":"M Kosaka","year":"2020","unstructured":"Kosaka, M., Zhang, D., Wong, S. & Yan, Z. NADPH-independent inactivation of CYP2B6 and NADPH-dependent inactivation of CYP3A4\/5 by PBD: potential implication for assessing covalent modulators for time-dependent inhibition. Drug Metab. Dispos. 48, 655\u2013661 (2020).","journal-title":"Drug Metab. Dispos."},{"key":"505_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1124\/dmd.105.007633","volume":"34","author":"BW Ogilvie","year":"2006","unstructured":"Ogilvie, B. W. et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos. 34, 191\u2013197 (2006).","journal-title":"Drug Metab. Dispos."},{"key":"505_CR30","doi-asserted-by":"crossref","unstructured":"Gibaldi M., Perrier D. Pharmacokinetics. Published by CRC Press, 2nd Edn (1982).","DOI":"10.1201\/b14095"},{"key":"505_CR31","doi-asserted-by":"publisher","first-page":"112028","DOI":"10.1016\/j.ejmech.2019.112028","volume":"189","author":"L Zhou","year":"2020","unstructured":"Zhou, L. et al. Design and synthesis of alpha-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation. Eur. J. Med. Chem. 189, 112028 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"505_CR32","doi-asserted-by":"publisher","first-page":"eabn2707","DOI":"10.1126\/scisignal.abn2707","volume":"15","author":"AM Kurimchak","year":"2022","unstructured":"Kurimchak, A. M. et al. The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. Sci. Signal. 15, eabn2707 (2022).","journal-title":"Sci. Signal."},{"key":"505_CR33","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1124\/dmd.119.086744","volume":"47","author":"D Zhang","year":"2019","unstructured":"Zhang, D. et al. Drug concentration asymmetry in tissues and plasma for small molecule-related therapeutic modalities. Drug Metab. Dispos. 47, 1122\u20131135 (2019).","journal-title":"Drug Metab. Dispos."},{"key":"505_CR34","doi-asserted-by":"publisher","first-page":"8713","DOI":"10.1021\/acs.jmedchem.2c00502","volume":"65","author":"R Zang","year":"2022","unstructured":"Zang, R. et al. Design and measurement of drug tissue concentration asymmetry and tissue exposure-effect (Tissue PK-PD) evaluation. J. Med. Chem. 65, 8713\u20138734 (2022).","journal-title":"J. Med. Chem."},{"key":"505_CR35","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.abl5829","volume":"378","author":"K Lou","year":"2022","unstructured":"Lou, K. et al. IFITM proteins assist cellular uptake of diverse linked chemotypes. Science 378, 1097\u20131104 (2022).","journal-title":"Science"},{"key":"505_CR36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.cell.2015.07.022","volume":"162","author":"A Cesar-Razquin","year":"2015","unstructured":"Cesar-Razquin, A. et al. A call for systematic research on solute carriers. Cell 162, 478\u2013487 (2015).","journal-title":"Cell"},{"key":"505_CR37","first-page":"24","volume":"1","author":"H Inuzuka","year":"2022","unstructured":"Inuzuka, H., Liu, J., Wei, W. & Rezaeian, A. H. PROTACs technology for treatment of Alzheimer\u2019s disease: advances and perspectives. Acta Mater. Med. 1, 24\u201341 (2022).","journal-title":"Acta Mater. Med."},{"key":"505_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33430-6","volume":"13","author":"C Kofink","year":"2022","unstructured":"Kofink, C. et al. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nat. Commun. 13, 5969 (2022).","journal-title":"Nat. Commun."},{"key":"505_CR39","doi-asserted-by":"publisher","first-page":"6266","DOI":"10.1021\/acs.analchem.9b01016","volume":"91","author":"JA Barry","year":"2019","unstructured":"Barry, J. A. et al. Multicenter validation study of quantitative imaging mass spectrometry. Anal. Chem. 91, 6266\u20136274 (2019).","journal-title":"Anal. Chem."},{"key":"505_CR40","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1021\/acsmedchemlett.3c00231","volume":"14","author":"G Apprato","year":"2023","unstructured":"Apprato, G., Ermondi, G. & Caron, G. The quest for oral PROTAC drugs: evaluating the weaknesses of the screening pipeline. ACS Med Chem Lett 14, 879\u2013883 (2023).","journal-title":"ACS Med Chem Lett"},{"key":"505_CR41","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.3390\/pharmaceutics15082098","volume":"15","author":"P Kou","year":"2023","unstructured":"Kou, P. et al. Development of liposome systems for enhancing the PK properties of bivalent PROTACs. Pharmaceutics 15, 2098 (2023).","journal-title":"Pharmaceutics"},{"key":"505_CR42","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1039\/D2CS00141A","volume":"51","author":"PS Dragovich","year":"2022","unstructured":"Dragovich, P. S. Degrader-antibody conjugates. Chem. Soc. Rev. 51, 3886\u20133897 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"505_CR43","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1021\/acs.jmedchem.2c00339","volume":"65","author":"PS Dragovich","year":"2022","unstructured":"Dragovich, P. S. Antibody-drug conjugates for immunology. J. Med. Chem. 65, 4496\u20134499 (2022).","journal-title":"J. Med. Chem."},{"key":"505_CR44","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1021\/acs.jmedchem.0c01845","volume":"64","author":"PS Dragovich","year":"2021","unstructured":"Dragovich, P. S. et al. Antibody-mediated delivery of chimeric BRD4 degraders. Part 1: exploration of antibody linker, payload loading, and payload molecular properties. J. Med. Chem. 64, 2534\u20132575 (2021).","journal-title":"J. Med. Chem."},{"key":"505_CR45","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1021\/acs.jmedchem.0c01846","volume":"64","author":"PS Dragovich","year":"2021","unstructured":"Dragovich, P. S. et al. Antibody-mediated delivery of chimeric BRD4 degraders. Part 2: improvement of in vitro antiproliferation activity and in vivo antitumor efficacy. J. Med. Chem. 64, 2576\u20132607 (2021).","journal-title":"J. Med. Chem."},{"key":"505_CR46","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2217\/nnm-2020-0156","volume":"15","author":"A Saraswat","year":"2020","unstructured":"Saraswat, A. et al. Nanoformulation of PROteolysis targeting chimera targeting \u2018undruggable\u2019 c-Myc for the treatment of pancreatic cancer. Nanomedicine (Lond) 15, 1761\u20131777 (2020).","journal-title":"Nanomedicine (Lond)"},{"key":"505_CR47","doi-asserted-by":"crossref","unstructured":"O\u2019Brien Laramy M. N., Luthra S., Brown M. F., Bartlett D. W. Delivering on the promise of protein degraders. Nat. Rev. Drug Discov. 22, 410\u2013427 (2023).","DOI":"10.1038\/s41573-023-00652-2"},{"key":"505_CR48","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan, S. et al. A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity. Nat Med 25, 1938\u20131947 (2019).","journal-title":"Nat Med"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00505-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00505-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00505-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T10:06:53Z","timestamp":1715854013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00505-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["505"],"URL":"https:\/\/doi.org\/10.1038\/s43856-024-00505-y","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"24 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: D.Z., B.M., P.D., L.M., S.C., E.Chen., X.Y., J.L., E.Chan, X.Z., Y.C., E.L., R.Y., C.K., and C.H. are employees of Genentech, Roche and have stocks, and\/or options of Roche. J.P. and E.B. are employees of Arvinas and have stocks, and\/or options of Arvinas.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}